A Phase 3 interventional study of Sitagliptin and Metformin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2018-08-22.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 62nd largest by enrollment of the 287 interventional ones that give a count, is one of 23 that started in 2012, is one of 72 in phase 3, and was the 148th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
University of California, San Francisco · Sites in United States
Ages 10–21 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–65
Lille Catholic University · Sites in France
Ages 18–40
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 20 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 31 · Phase 3 77 · Phase 4 98
First in 1996; this study’s year is marked. 23 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 337 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 287 interventional studies. Of the 235 that completed or were terminated, 89 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 293 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 67th largest by enrollment of the 170 interventional ones that give a count, is one of 20 that started in 2012, is one of 86 in phase 3, and was the 126th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
7 of the studies testing metformin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02087826Massachusetts General HospitalStudy of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS | 2026-12 |
| NCT06120881University of California, San FranciscoPrecision Dosing of Metformin in Youth With T2D | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, from their registry updates:
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of the addition of metformin once daily (q.d.) or twice daily (b.i.d.) to sitagliptin monotherapy in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control with diet/exercise therapy and sitagliptin monotherapy. The primary hypotheses are that the addition of metformin 250 mg b.i.d. or metformin 500 mg q.d. is superior to the addition of placebo on the change from baseline in hemoglobin A1c (HbA1c) at 24 weeks and that the addition of metformin 500 mg q.d. is non-inferior to the addition of metformin 250 mg b.i.d. on the change from baseline in HbA1c at 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive sitagliptin daily (continuing their pre-study dose), 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening.
Drug: Sitagliptin · Drug: Metformin · Drug: Placebo
Participants will receive sitagliptin daily (continuing their pre-study dose), 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening.
Drug: Sitagliptin · Drug: Metformin · Drug: Placebo
Participants will receive sitagliptin daily (continuing their pre-study dose), 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening.
Drug: Sitagliptin · Drug: Placebo
Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)
Also known as: MK-0431/ONO-5435
Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks
Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks
Placebo to match metformin 250 mg tablets, orally, for 24 weeks
Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)
Based on a constrained longitudinal data analysis (cLDA) model with terms for treatment, other prior antihyperglycemic agent (AHA) therapy status other than sitagliptin (yes/no), study drug regimen (just before meal/after meal), sitagliptin dosage (50 mg/100 mg), time and the interaction of time by treatment, time by other prior AHA therapy status, time by study drug regimen, time by sitagliptin dosage and study drug regimen by sitagliptin dosage, with a constraint that the mean baseline is the same for all treatment groups.
Time frame: Baseline and Week 24
Percentage of Participants Who Experienced at Least One Adverse Event
Time frame: Up to 26 weeks
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
Time frame: Up to 24 weeks
Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG)
Based on a cLDA model with terms for treatment, other prior AHA therapy status other than sitagliptin (yes/no), study drug regimen (just before meal/after meal), sitagliptin dosage (50 mg/100 mg), time and the interaction of time by treatment, time by other prior AHA therapy status, time by study drug regimen, time by sitagliptin dosage and study drug regimen by sitagliptin dosage, with a constraint that the mean baseline is the same for all treatment groups.
Time frame: Baseline and Week 24
| Milestone | Metformin 500 mg q.d. | Metformin 250 mg b.i.d. | Placebo |
|---|---|---|---|
| Started | 138 | 133 | 66 |
| Completed | 130 | 122 | 58 |
| Not completed | 8 | 11 | 8 |
| Withdrew: Adverse event | 2 | 4 | 1 |
| Withdrew: Lack of efficacy | 3 | 2 | 5 |
| Withdrew: Participant moved or relocated | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 4 | 2 |
| Withdrew: Other | 1 | 1 | 0 |
Based on a constrained longitudinal data analysis (cLDA) model with terms for treatment, other prior antihyperglycemic agent (AHA) therapy status other than sitagliptin (yes/no), study drug regimen (just before meal/after meal), sitagliptin dosage (50 mg/100 mg), time and the interaction of time by treatment, time by other prior AHA therapy status, time by study drug regimen, time by sitagliptin dosage and study drug regimen by sitagliptin dosage, with a constraint that the mean baseline is the same for all treatment groups.
| Percent of glycosylated hemoglobin | Metformin 500 mg q.d. | Metformin 250 mg b.i.d. | Placebo |
|---|---|---|---|
| Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) | -0.434 (-0.553 to -0.315) | -0.587 (-0.708 to -0.467) | 0.091 (-0.073 to 0.255) |
Based on a cLDA model with terms for treatment, other prior AHA therapy status other than sitagliptin (yes/no), study drug regimen (just before meal/after meal), sitagliptin dosage (50 mg/100 mg), time and the interaction of time by treatment, time by other prior AHA therapy status, time by study drug regimen, time by sitagliptin dosage and study drug regimen by sitagliptin dosage, with a constraint that the mean baseline is the same for all treatment groups.
| mg/dL | Metformin 500 mg q.d. | Metformin 250 mg b.i.d. | Placebo |
|---|---|---|---|
| Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) | -9.02 (-13.74 to -4.30) | -11.27 (-16.07 to -6.46) | 7.32 (0.86 to 13.79) |
| Percentage of participants | Metformin 500 mg q.d. | Metformin 250 mg b.i.d. | Placebo |
|---|---|---|---|
| Percentage of Participants Who Experienced at Least One Adverse Event | 65.9 | 67.7 | 60.6 |
| Participants | Metformin 500 mg q.d. | Metformin 250 mg b.i.d. | Placebo |
|---|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to an Adverse Event | 2 | 3 | 1 |
Collected over Up to 26 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Metformin 500 mg q.d. | — | 4/138 (2.9%) | 29/138 (21%) |
| Metformin 250 mg b.i.d. | — | 2/133 (1.5%) | 35/133 (26.3%) |
| Placebo | — | 0/66 (0%) | 8/66 (12.1%) |
| Event | Metformin 500 mg q.d. | Metformin 250 mg b.i.d. | Placebo |
|---|---|---|---|
| Anaphylactic reactionImmune system disorders | 0/138 | 1/133 | 0/66 |
| Brain stem infarctionNervous system disorders | 0/138 | 1/133 | 0/66 |
| GastroenteritisInfections and infestations | 1/138 | 0/133 | 0/66 |
| Sternal fractureInjury, poisoning and procedural complications | 1/138 | 0/133 | 0/66 |
| Cerebral infarctionNervous system disorders | 1/138 | 0/133 | 0/66 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 1/138 | 0/133 | 0/66 |
| Event | Metformin 500 mg q.d. | Metformin 250 mg b.i.d. | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 17/138 | 28/133 | 7/66 |
| ConstipationGastrointestinal disorders | 8/138 | 5/133 | 0/66 |
| Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 8/138 | 4/133 | 1/66 |
All participants as treated population defined as all randomized participants.
| Age, Continuous(Years) | Metformin 500 mg q.d. | Metformin 250 mg b.i.d. | Placebo | Total |
|---|---|---|---|---|
| Mean | 59.46 ± 9.61 | 59.65 ± 9.22 | 60.05 ± 9.30 | 59.65 ± 9.37 |
| Sex: Female, Male(Participants) | Metformin 500 mg q.d. | Metformin 250 mg b.i.d. | Placebo | Total |
|---|---|---|---|---|
| Female | 52 | 46 | 28 | 126 |
| Male | 86 | 87 | 38 | 211 |
| Hemoglobin A1c (HbA1c)(Percent of glycosylated hemoglobin) | Metformin 500 mg q.d. | Metformin 250 mg b.i.d. | Placebo | Total |
|---|---|---|---|---|
| Mean | 7.60 ± 0.83 | 7.40 ± 0.68 | 7.53 ± 0.77 | 7.51 ± 0.76 |
| Fasting plasma glucose (FPG)(mg/dL) | Metformin 500 mg q.d. | Metformin 250 mg b.i.d. | Placebo | Total |
|---|---|---|---|---|
| Mean | 158.58 ± 32.45 | 148.98 ± 26.27 | 154.27 ± 27.51 | 153.95 ± 29.42 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
No publications or documents are linked to this record.
Ran from Feb 2012 to primary completion in Mar 2013, 12 months.
Results were first posted in Mar 2014, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 12 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin